"High efficacy of carvedilol in lowering HVPG was confirmed.Predictive factors of treatment response are inflammatory changes and endothelial activation.Presence of eNOS polymorphism in cirrhotics dosn\u00B4t differ from healthy control."@en . "http://www.isvav.cz/projectDetail.do?rowId=NK7747"^^ . "eNOS polymorphism" . . "Oxidative stress" . "Portovenous gradient" . . "Liver cirrhosis;portal hypertension complicati;Portovenous gradient;Oesophageal varices bleeding;cytokines;eNOS polymorphism;Oxidative stress;Pharmacotherapy"@en . . "Development of portal hypertension complication can be prevented by pharmacotherapy. Study asses the influence of carvedilol on HVPG and complications development - variceal bleeding, ascites, SBP, hepatopulmonary syndrome. The significance of eNOS polymorphism in portal hypertension is not determined. The aim of study is to establish the correlation between this polymorphism and degree of portal hypertension and presence of complications. Predictive factors of response to portal hypertension therapy are not known. Study evaluates the correlation between treatment response and presence of eNOS polymorphism, concentration of endothelin 1, TNFalfa, Il-2, Il-6, F2 isoprostane, NO production. Study evaluates nonabsorbable disaccharides and antibiotics applied for HE control for their possible impact on the HVPG value and cytokines concentration."@en . . . "Pharmacological manipulation of portal hypertension and correlation to genetic eNOS polymorfism, exidative stress and vasoactive cytokines."@en . . . . . "Byla zji\u0161t\u011Bna vysok\u00E1 \u00FA\u010Dinnost carvedilolu na sn\u00ED\u017Een\u00ED HVPG u cirhotik\u016F.Prediktivn\u00EDmi faktory jeho \u00FA\u010Dinku je v\u00FD\u0161e z\u00E1n\u011Bt.reakce a aktivace endotelu.Zastoupen\u00ED polymorfism\u016F eNOS se u cirhotik\u016F neli\u0161\u00ED od b\u011B\u017En\u00E9 populace."@cs . . "Farmakologick\u00E9 ovlivn\u011Bn\u00ED port\u00E1ln\u00ED hypentenze a vztah ke genetick\u00E9mu polymorfismu eNOS, oxida\u010Dn\u00EDmu stresu a vazoaktivn\u00EDm tk\u00E1\u0148ov\u00FDm p\u016Fsobk\u016Fm." . "NK7747" . . "Oesophageal varices bleeding" . . "7"^^ . "portal hypertension complicati" . . "7"^^ . . "cytokines" . "Rozvoj komplikac\u00ED port\u00E1ln\u00ED hypertenze lze ovlivnit preventivn\u00ED l\u00E9\u010Dbu. Studie hodnot\u00ED vliv l\u00E9\u010Dby carvedilolem na v\u00FD\u0161i port\u00E1ln\u00ED hypertenze a rozvoj komplikac\u00ED - kv\u00E1cen\u00ED z j\u00EDcnov\u00FDch varix\u016F, hepatopulmon\u00E1ln\u00ED syndrom, ascites, SBP. V\u00FDznam genetick\u00FDch polymorfism\u016F eNOS pro v\u00FD\u0161i port\u00E1ln\u00ED hypertenze a p\u0159\u00EDtomnost komplikac\u00ED nen\u00ED dosud objasn\u011Bn. C\u00EDlem studie je tento vztah objasnit. Nejsou zn\u00E1my prediktivn\u00ED faktory odpov\u011Bdi na l\u00E9\u010Dbu port\u00E1ln\u00ED hypertenze, studie posuzuje efekt l\u00E9\u010Dby v z\u00E1vislosti na p\u0159\u00EDtomnosti polymorfism\u016F eNOS, hodnot\u00E1ch endotelinu 1, TNFalfa, Il-2, Il-6, parametru oxida\u010Dn\u00EDho stresu (F2 isoprostan\u016F) a produkci NO. Studie hodnot\u00ED mo\u017Enost ovlivn\u011Bn\u00ED port\u00E1ln\u00ED hypertenze l\u00E9\u010Dbou m\u011Bn\u00EDc\u00ED st\u0159evn\u00ED mikrofl\u00F3ru a pou\u017E\u00EDvanou v l\u00E9\u010Db\u011B jaten\u00ED encefalopatie." . . "2006-06-23+02:00"^^ . . "0"^^ . "1"^^ . . . . "0"^^ . "Liver cirrhosis" .